Genprex, Inc. - Common Stock (GNPX)
0.4316
+0.1416 (48.83%)
NASDAQ · Last Trade: Apr 3rd, 10:46 PM EDT
Detailed Quote
Previous Close | 0.2900 |
---|---|
Open | 0.3200 |
Bid | 0.3807 |
Ask | 0.3878 |
Day's Range | 0.2853 - 0.4366 |
52 Week Range | 0.2200 - 4.090 |
Volume | 63,227,507 |
Market Cap | 25.64M |
PE Ratio (TTM) | -3.597 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 8,362,613 |
Chart
About Genprex, Inc. - Common Stock (GNPX)
Genprex Inc is a biotechnology company focused on developing innovative gene therapy treatments for cancer and diabetes. Their primary aim is to enhance the efficacy of existing therapies and improve patient outcomes through the use of their proprietary Oncoprex immunogene therapy, which targets various types of tumors. The company is dedicated to advancing its promising treatments through clinical trials and aims to address significant unmet medical needs in oncology. With a strong emphasis on research and development, Genprex seeks to create transformative therapies that can benefit patients and improve their quality of life. Read More
News & Press Releases
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · April 3, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025
Via Benzinga · April 3, 2025
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · April 2, 2025
Via Benzinga · April 2, 2025
Via Benzinga · April 2, 2025
Via Benzinga · March 18, 2025

Via Benzinga · February 11, 2025

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.
Via Benzinga · November 4, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 24, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024